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Duloxetine versus Routine Care in the Long-Term
Management of Diabetic Peripheral Neuropathic Pain
JOEL RASKIN, M.D., F.R.C.P.C.,1 TIMOTHY R. SMITH, M.D., R.Ph., F.A.C.P.,2
KAR WONG, Ph.D., YILI LU PRITCHETT, Ph.D.,3 DEBORAH N. D’SOUZA, Ph.D., M.B.A.,3
SMRITI IYENGAR, Ph.D.,3 and J.F. WERNICKE, Ph.D., M.D.3

ABSTRACT
Introduction: Duloxetine hydrochloride is a dual reuptake inhibitor of both serotonin and
norepinephrine. In the present open-label study, the safety of duloxetine at a fixed-dose of
60 mg twice daily (BID) for up to 52 weeks was evaluated and compared to routine care in
the therapy of patients diagnosed with diabetic peripheral neuropathic pain (DPNP).
Methods: Patients who completed a 13-week, double-blind, duloxetine and placebo acute
therapy period were rerandomly assigned in a 2:1 ratio to therapy with duloxetine 60 mg BID
(N  161) or routine care (N  76) for an additional 52 weeks. Routine care consisted primarily of gabapentin, amitriptyline, and venlafaxine. The study included male or female outpatients 18 years of age or older with a diagnosis of DPNP caused by type 1 or type 2 diabetes.
Results: A higher percentage of routine care-treated patients experienced 1 or more serious
adverse events. No statistically significant therapy-group difference was observed in the overall incidence of treatment-emergent adverse events (TEAEs). The TEAEs reported by 10% or
more of duloxetine 60 mg BID-treated patients were nausea, and by the routine care-treated
patients were peripheral edema, pain in the extremity, somnolence, and dizziness. Duloxetine did not appear to adversely affect glycemic control, lipid profiles, nerve function, or the
course of DPNP. There were no statistically significant therapy-group differences observed
in the 36-item Short-Form Health Survey subscales or in the EuroQol 5-Dimension Questionnaire.
Conclusions: In this study, duloxetine was safe and well tolerated compared to routine care
in the long-term management of patients with DPNP.

experience pain.2–4 This pain is often described as
an “aching, burning, stabbing, or tingling” sensation3 and is characterized by hyperalgesia,
paresthesia, and allodynia.5–7
The neurotransmitters serotonin (5-HT) and
norepinephrine (NE) have been implicated in the
modulation of endogenous analgesic mechanisms via the descending inhibitory pain path-
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D

is a common disease, affecting approximately 6.3% (18.2 million) of
the population in the United States.1 Approximately 30%–60% of patients with diabetes develop long-term complications of peripheral neuropathy, and up to 10%–20% of these patients
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ways in the brain and spinal cord.8,9 In pathologic
pain states, these endogenous pain inhibitory
mechanisms may be dysfunctional. This may contribute to the central sensitization and hyperexcitability of the spinal and supraspinal pain transmitting pathways that may manifest as persistent
pain.10
Tricyclic antidepressants (TCAs) with reuptake
inhibitory activity for both 5-HT and NE have been
widely used in the management of DPNP.11,12 Hypothetically, dual reuptake inhibitors unburdened
by the undesirable pharmacologic effects of TCAs
should be better tolerated and more effective in
managing diabetic peripheral neuropathic pain
(DPNP). This hypothesis is supported by the finding that amitriptyline (5-HT and NE reuptake inhibitor) is superior to desipramine (NE reuptake
inhibitor), which is superior to fluvoxamine (5-HT
reuptake inhibitor) in providing pain relief.13 In a
crossover study comparing 4-week treatment periods, venlafaxine and imipramine were found
to be superior to placebo in relieving DPNP.14
Other drugs reported to manage DPNP are “anticonvulsants,”15,16 selective serotonin reuptake inhibitors,17 controlled-release oxycodone,18,19 and
the synthetic cannabinoid CT-3.20
Duloxetine hydrochloride (Cymbalta®, Eli Lilly
and Company, Indianapolis, IN) is a selective 5HT and NE reuptake inhibitor that is relatively
balanced in its affinity for both 5-HT and NE
reuptake inhibition.21 Because central sensitization is believed to be involved in the development
and maintenance of chronic neuropathic pain, including DPNP, patients with DPNP may benefit
from duloxetine therapy. Duloxetine (40 to 120 mg
daily) has been shown to be safe and effective in
the treatment of major depression.22–26 Duloxetine
is the first Food and Drug Administration (FDA)approved prescription drug for the management
of DPNP. In a randomized, controlled, 12-week
trial comparing duloxetine 60 mg once daily (QD)
and duloxetine 60 mg twice daily (BID) or duloxetine 20 mg QD with placebo in 457 patients with
DPNP and without depression, duloxetine was
found to be effective and safe for DPNP management.27 Based on this evidence, two more independent 12-week acute therapy studies were conducted, and these studies confirmed the safety and
efficacy of duloxetine 60 mg QD and 60 mg BID
in the management of patients with DPNP.28,29
The study presented here was conducted in order
to evaluate the safety, as well as the impact of therapy on patient-reported health outcomes with up
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to 65 weeks exposure with duloxetine 60 mg BID
or routine care. It is a one-year extension of an
acute study, the results of which were previously
reported.28

Study objectives
The objectives of this study were to evaluate
the safety of duloxetine 60 mg BID over a 52week open-label extension period, to evaluate the
safety of duloxetine 60 mg BID for up to 65-week
exposure with regard to the progression of diabetic complications, and to assess the impact of
treatment with duloxetine 60 mg BID and routine
care on patient-reported health outcomes.

METHODS
Study design and treatments
This study was a 52-week, randomized, openlabel, extension trial comparing duloxetine and
routine care in patients with DPNP. This multicenter study included 26 principal investigators,
and was conducted at 27 investigative sites in the
United States and Puerto Rico. The acute therapy
phase of this study was 12 weeks in duration,
with an additional 1-week drug-tapering phase.
The extension therapy phase was 52 weeks, making the total duration of the study 65 weeks. Only
those patients who completed the acute period of
the study, independent of treatment assignment,
were allowed to continue into the extension phase
of the study. Patients were rerandomized (2:1) to
either duloxetine therapy or routine care. Patients
rerandomized to the duloxetine therapy group
began on 60 mg QD for 3 days and then received
60 mg BID until 1 week prior to week 52 of the
extension phase of the study, at which time the
patient was instructed to reduce the dose of duloxetine to 60 mg QD. Patients could reduce their
dose of duloxetine to 60 mg QD if they could not
tolerate a dose of 60 mg BID.
Duloxetine was provided as 30-mg capsules
and patients were instructed to take 4 capsules
orally each day. Patients were seen after 1 week
(week 14) of treatment with either duloxetine or
routine care. They were then seen again at weeks
17, 21, 25, 33, 41, 49, 57, and 65 of treatment. Compliance was defined as taking between 80% and
120% of the study medication prescribed for each
interval.
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The routine care group was treated with therapies that the investigator and the patient believed permitted the optimal benefit to the patient. The duloxetine-treated patients received
most therapies, including nonmedicinal therapy
offered to the routine care group, with the exception of antidepressants, anticonvulsants, and
antipsychotics. During this period, patients in
both treatment groups were permitted to supplement their analgesia with acetaminophen,
nonsteroidal anti-inflammatory drugs (NSAIDs),
or opioid analgesics.
The ethical review boards provided approval
of the study protocol in accordance with the principles of the Declaration of Helsinki, and all patients provided written informed consent after
the study was explained and prior to the performance of any protocol procedures and administration of the study drug.

Entry criteria
As detailed in Raskin et al.,29 patients were eligible for the study if they were 18 years or older,
and presented with pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus. The pain had to begin in the feet
and with relatively symmetrical onset. The daily
pain should have been present for at least 6
months; neuropathy was confirmed by a score of
at least 3 on the Michigan Neuropathy Screening
Instrument (MNSI).30 Patients had to have a
mean score of 4 or more when assessed by 24hour average pain severity on an 11-point Likert
scale, stable glycemic control, and a glycosylated
hemoglobin (HbA1c) of 12% or more. Some of the
reasons for patient exclusion were serious or unstable illness, current (1 year) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
Axis I diagnosis of major depressive disorder, historical exposure to drugs known to cause neuropathy, a positive urine drug screen for substances of abuse, or excluded medication.

Safety assessments
Safety of duloxetine over the 52-week open-label extension period was measured by discontinuation rates, treatment-emergent adverse events
(TEAEs), laboratory assessments, including lipid
profile and glycosylated hemoglobin (HbA1c),
weight, and electrocardiograms (ECGs). A TEAE
was defined as an event that first occurred or
worsened after random assignment. Vital signs
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including heart rate and blood pressure were
recorded. A patient considered to have sustained
elevation in blood pressure after randomization
met the following criteria: sitting diastolic blood
pressure 85 mm Hg or more and increase from
baseline of 10 mm Hg for 3 consecutive visits, or
sitting systolic blood pressure 130 mm Hg or
more and increase from baseline of 10 mm Hg for
3 consecutive visits.
The safety of duloxetine for up to 65 weeks was
also evaluated with regard to the progression of
diabetic complications, as measured by the MNSI
(neuropathy progression), electrophysiology assessments (measures included ulnar F-wave, ulnar distal sensory latency, peroneal F-wave,
peroneal compound muscle action potential
[CMAP]), microalbumin/creatinine ratio (nephropathy progression), and an ophthalmologic
examination (measures for retinopathy progression included worsening of visual acuity, procedures required, reasons for photocoagulation,
and reasons for vitrectomy). Changes from baseline to endpoint were assessed where baseline
refers to values collected prior to the acute therapy phase, and endpoint refers to values collected
at week 65 of treatment or at an early discontinuation visit between week 41 and week 65 of
treatment.
All data were collected at week 65 of treatment
or at an early discontinuation visit between
weeks 14 and 65 of treatment. In addition, data
on vital signs, adverse events, and concomitant
medications were collected at each visit starting
from week 14 until week 65 of treatment, ECG
data were collected at weeks 14 and 49 of treatment, and samples for HbA1c and clinical chemistry profiles were collected at week 49 of treatment.

Health outcome measures
The impact of therapy with duloxetine 60 mg
BID and routine care on patient-reported health
outcomes was measured by the 36-item Short
Form Health Survey (SF-36)31 and the EuroQol
Questionnaire—5-Dimension (EQ-5D).32 The SF36 was completed by the patient to measure how
the patient perceives general health status. The
EQ-5D was completed by the patient to measure
how severe the patient perceived general health.
In the SF-36 and EQ-5D index, baseline refers
to values collected at the end of the acute therapy phase, and the endpoint refers to values col-
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lected at week 65 of treatment or at an early discontinuation visit between week 14 and week 65
of treatment.

Statistical analysis
All analyses were conducted on an intent-totreat basis. Therapy effects were evaluated based
on a two-sided significance level of 0.05, and interaction effects at 0.10. No adjustments for multiple comparisons were made. Application software (SAS, Version 8.0 SAS, Inc., Cary, NC) was
used to perform all statistical analyses.
For categorical data, therapy group comparisons were made using Fisher’s exact test. These
include reasons for patient disposition, patient
characteristics (e.g., gender, origin, types of diabetic mellitus), concomitant medication use, and
safety endpoints (e.g., adverse events). For continuous data, therapy group comparisons were
made using a type III sum-of-squares analysis of
variance (ANOVA) model, with the terms of therapy and investigator. These include patient characteristics at baseline (e.g., age, height, and
weight, duration of diabetes, duration of diabetic
neuropathy, and Michigan Neuropathy Screening Score), duration of exposure, change from
baseline for vital signs, ECG parameters, and
ranked laboratory assessments.
Assessments of change from baseline for the
MNSI, electrophysiology measures, and ranked
microalbumin/creatinine ratio were made using
a type II sum-of-squares ANOVA model with
terms of investigator, acute therapy (duloxetine or
placebo), extension therapy, and acute therapy by
extension therapy. Testing the significance of the
therapy factor in the extension phase was of primary interest. Ophthalmologic exams that summarized worsening in visual acuity and the types
of procedures required during the study were analyzed using the Cochran-Mantel-Haenszel general association test, controlling for acute therapy.
For the EQ-5D index, and each of the SF-36 domains, including physical and mental component
summaries, therapy-group differences in the
mean change from baseline to endpoint were
evaluated using a type III sum-of-squares analysis of covariance (ANCOVA) model with terms
of baseline, investigator, and therapy in the
model. In addition, investigator-by-therapy interaction was assessed by adding this term to the
above model with a type II estimate approach.
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RESULTS
Patient disposition, demographics, and
disease characteristics
Two hundred thirty-seven patients who completed the acute therapy period were rerandomly
assigned to therapy with either duloxetine 60 mg
BID (N  161) or routine care (N  76). There
were no statistically significant therapy-group
differences observed in any of the patient demographics or disease characteristics (Table 1). The
majority of the patients were male (61.2%) and
Caucasian (78.5%). The mean patient age was 60
years and the mean MNSI score was 5.7. The
mean duration of diabetes in all patients was 9.9
years with type 2 diabetes being the most prevalent (90%).
A total of 179 (75.5%) patients completed the
extension phase of the study (116 [72%] duloxetine-treated and 63 [82.9%] routine care-treated
group). The reasons for study discontinuation are
summarized in Table 2. There were no statistically significant differences observed between
routine care and duloxetine therapy for any of the
reasons for discontinuation.

Concomitant medications
Table 3 summarizes concomitant medications
used by at least 5% of patients. A statistically significant therapy-group difference was observed
with regard to concomitant use of Neurontin
(gabapentin), Lantus (insulin glargine injection),
Amaryl (glimerpiride), and Lasix (furosemide).
Neurontin (gabapentin) use was allowed only
in the routine care-treated group. A significantly
smaller percentage of duloxetine-treated patients
reported taking these medications. The most frequently reported concomitant medications used
by all patients were glucophage, aspirin, Avandia (rosiglitazone), Neurontin (gabapentin—for
routine care-treated group only), Lipitor (atorvastatin), Tylenol (acetaminophen), and Actos
(pioglitazone).
Table 4 presents medications used by patients in the routine care group for DPNP. The
most commonly used pain medications for routine care-treated patients included Neurontin
(gabapentin), Elavil (amitriptyline), Effexor-XR
(venlafaxine extended release), and Tylenol (acetaminophen).

DULOXETINE AND DIABETIC PERIPHERAL NEUROPATHIC PAIN
TABLE 1.

DEMOGRAPHICS

AND

Variable
Mean age, years, (SD)
Gender
Female, n (%)
Male, n (%)
Race (origin)
Caucasian, n (%)
Hispanic, n (%)
African, n (%)
Western Asian, n (%)
Other, n (%)
Mean weight, kg (SD)
Type of Diabetes Mellitus
Type 1, n (%)
Type 2, n (%)
Mean duration of diabetes, years (SD)
Mean duration of diabetic neuropathy, years (SD)
Mean MNSI (SD)
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BASELINE ASSESSMENTS
Duloxetine
(N  161)

Routine care
(N  76)

59.7 (10.7)

60.6 (10.3)

62 (38.5)
99 (61.5)

30 (39.5)
46 (60.5)

128
26
4
1
2
101

(79.5)
(16.1)
(2.5)
(0.6)
(1.2)
(24)

58
14
2
0
2
105

(76.3)
(18.4)
(2.6)
(0.0)
(2.6)
(25)

15
146
10.3
3.9
5.6

(9.3)
(90.7)
(9.5)
(4.5)
(1.5)

8
68
9.3
3.1
5.8

(10.5)
(89.5)
(9.1)
(2.5)
(1.5)

MNSI, Michigan Neuropathy Screening Instrument; SD, standard deviation

Safety
Extent of exposure. The mean duration of exposure (days) was significantly longer (p  0.032)
for routine care-treated patients (mean days
[standard deviation [SD]: 336.4 [70.8]) compared
to duloxetine-treated patients (mean days [SD]:
304.2 [116.1]). The median duration was similar
for both groups and was approximately 1 year.
The total patient–years of exposure was 134.1 for
the duloxetine-treated group and 70.0 for the routine care-treated group.
Deaths. During the study, 4 deaths (2 duloxetine-treated patients and 2 routine care-treated
patients) occurred, which were considered by the
investigators to be unrelated to the study drug or
TABLE 2.

the protocol procedures. The cause of death in the
2 duloxetine-treated patients was myocardial infarction and acute myocardial infarction, and in
the 2 routine care-treated patients was myocardial infarction and pulmonary embolism. The
mortality rate per 100,000 patient–years was
1491.5 for the duloxetine-treated group, 2857.6 for
the routine care-treated group, and 1960.0 for the
combined population.
Serious adverse events. During the study, a significantly higher percentage of routine caretreated patients experienced 1 or more serious adverse events (SAE) (28.9% routine care-treated
versus 16.8% duloxetine-treated; p  0.039). A
significant therapy group difference was also observed in congestive heart failure, with a higher

PATIENT DISPOSITION

Completed 52-week study
Discontinued because of:
Adverse event
Death
Unable to contact patient (lost to follow up)
Personal conflict or other patient decision
Physician decision
Protocol violation
Lack of efficacy

Duloxetine
(N  161)
%

Routine care
(N  76)
%

72.0

82.9

9.3
1.2
3.7
8.7
0.6
1.2
3.1

2.6
2.6
3.9
2.6
2.6
0.0
2.6
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TABLE 3.

CONCOMITANT MEDICATIONS USED

Drug name
Glucophage
Aspirin
Avandia
Neurontina
Lipitor
Tylenol
Actos
Lantusb
Amarylb
Zocor
Glyburide
Calcium
Metformin
Multivitamin
Hydrochlorothiazide
Lasixb
Lisinopril
Atenolol
Vitamin E
Diovan
Glucovance
Humalog
Vitamin C
Altace
Glipizide
Plavix
Acetaminophen
Nexium
Glucotrol
Insulin
Toprol XL
Accupril
Furosemide
Synthroid
Amoxicillin
Prevacid
Coumadin
Flomax
Folic Acid
Norvasc
Pravachol
Protonix
Viagra
Zithromax
ap

bp

BY AT

LEAST FIVE PERCENT

Duloxetine
(N  161)
n%
52
41
29
0
25
29
24
18
17
23
16
19
15
17
17
12
20
20
14
16
14
12
11
13
12
12
13
11
11
8
11
6
12
8
11
9
5
10
8
9
9
7
9
9

(32.3)
(25.5)
(18.0)
(0.0)
(15.5)
(18.0)
(14.9)
(11.2)
(10.6)
(14.3)
(9.9)
(11.8)
(9.3)
(10.6)
(10.6)
(7.5)
(12.4)
(12.4)
(8.7)
(9.9)
(8.7)
(7.5)
(6.8)
(8.1)
(7.5)
(7.5)
(8.1)
(6.8)
(6.8)
(5.0)
(6.8)
(3.7)
(7.5)
(5.0)
(6.8)
(5.6)
(3.1)
(6.2)
(5.0)
(5.6)
(5.6)
(4.3)
(5.6)
(5.6)

OF

PATIENTS
Routine care
(N  76)
n%
22 (28.9)
18 (23.7)
17 (22.4)
44 (57.9)
18 (23.7)
14 (18.4)
18 (23.7)
16 (21.1)
16 (21.1)
8 (10.5)
14 (18.4)
8 (10.5)
12 (15.8)
10 (13.2)
9 (11.8)
14 (18.4)
6 (7.9)
4 (5.3)
10 (13.2)
7 (9.2)
8 (10.5)
7 (9.2)
8 (10.5)
5 (6.6)
6 (7.9)
5 (6.6)
3 (3.9)
5 (6.6)
4 (5.3)
7 (9.2)
4 (5.3)
8 (10.5)
2 (2.6)
6 (7.9)
2 (2.6)
4 (5.3)
7 (9.2)
2 (2.6)
4 (5.3)
3 (3.9)
3 (3.9)
5 (6.6)
3 (3.9)
3 (3.9)

 0.001.
 0.05.

percentage of routine care-treated patients (5.3%)
experiencing this event versus duloxetine-treated
patients (0.6%).
Discontinuations because of adverse events. A total of 21 (8.9%) patients discontinued due to any
adverse event (including death): 4 (5.3%) routine
care-treated patients (1.3% occurrence of the following events: myocardial infarction, dementia,

fall, pulmonary embolism), and 17 (10.6%) duloxetine-treated patients (0.6% occurrence of the
following events: myocardial infarction, acute
myocardial infarction, agitation, chest pain, coronary artery disease, diabetic ketoacidosis, dizziness, dyskinesia, frequent bowel movements,
gamma-glutamyltransferase increased, hypercalcaemia, nausea, Parkinson’s disease, pruritus,
surgery, urinary retention, and vomiting).

DULOXETINE AND DIABETIC PERIPHERAL NEUROPATHIC PAIN
TABLE 4. SUMMARY OF MEDICATIONS USED BY
AT LEAST FIVE PERCENT OF PATIENTS IN THE
ROUTINE-CARE GROUP FOR TREATMENT OF
DIABETIC PERIPHERAL NEUROPATHIC PAIN
Routine care (N  76)
n (%)
Neurontin
Elavil
Amitriptyline
Effexor-XR
Effexor
Tylenol
Carbamazepine

44
11
6
9
7
8
4

(57.9)
(14.5)
(7.9)
(11.8)
(9.2)
(10.5)
(5.3)

Treatment-emergent adverse events. Of the patients randomly assigned in the study, 221
(93.2%) patients reported at least 1 TEAE. There
were no therapy-group differences in the overall
incidence of TEAEs. The TEAEs that occurred
with significant therapy-group differences included pain in extremity (15.8% versus 6.2%;
p  0.029), peripheral edema (15.8% versus 5.0%;
p  0.010), balance disorder (5.3% versus 0.6%;
p  0.038), erythema, feeling abnormal, and localized infections (3.9% versus 0%; p  0.032). All
of these TEAEs occurred at a higher rate in the

TABLE 5.

MEAN (STANDARD DEVIATION) CHANGE
N

Alkaline phosphatase (U/L)
ALT/SGPT (U/L)
AST/SGOT (U/L)a
Bicarbonate, HCO3 (mmol/L)
Total bilirubin (mol/L)
Calcium (mmol/L)
Chloride (mmol/L)a
Cholesterol (mmol/L)
Creatinine phosphokinase (U/L)
Creatinine (mol/L)
GGT (U/L)
Glucose, fasting (mmol/L)a
Inorganic phosphorus (mmol/L)
Potassium (mmol/L)
Sodium (mmol/L)
Total protein (g/L)
UA-PH (U)
UA-Specific gravitya
Urea nitrogen (mmol/L)
Uric acid (mol/L)a
Urine albumin (mg/L)
Urine creatinine (mmol/L)

153
152
150
152
152
153
153
153
152
153
153
152
153
153
153
153
134
134
153
153
118
118
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routine care-treated group. No significant therapy-group differences in TEAEs occurred in
which patients in the duloxetine-treated group
experienced the highest percentage of events.
In duloxetine-treated patients, the only TEAE reported by 10% or more of patients was nausea
(10.6%). In routine care-treated patients, the
TEAEs reported by 10% or more of patients were
peripheral edema and pain in extremity (15.8%),
somnolence (14.5%), and dizziness (13.2%). Most
TEAEs were mild or moderate. There were no
significant differences between therapy groups
in the overall incidence of TEAEs that were classified as severe. A greater percentage of routine
care-treated patients experienced pain in extremity, peripheral edema, and dyspnoea as severe and this difference was significant. There
were no significant therapy-group differences
observed in the treatment-emergent abnormal
laboratory values at any time for blood chemistry
and urinalysis.
Analysis of chemistry/urinalysis. Table 5 summarizes mean change in chemistry analytes and urinalysis from baseline to endpoint. There was a
slight, but significant, therapy-group difference
in mean change for aspartate transaminase, chlo-

FROM

BASELINE

TO

END POINT

Duloxetine 60 mg BID
4.99
1.96
1.96
1.41
0.55
0.01
3.14
0.14
6.93
1.51
0.10
0.30
0.01
0.02
1.16
0.74
0.02
0.00
0.19
8.69
18.55
0.60

(22.24)
(12.40)
(10.09)
(3.00)
(3.08)
(0.12)
(3.47)
(1.10)
(122.16)
(16.04)
(32.57)
(4.34)
(0.19)
(0.39)
(3.46)
(3.52)
(0.79)
(0.01)
(1.88)
(61.82)
(300.97)
(6.27)

IN

LABORATORY VALUES
N
69
69
69
69
69
69
69
69
69
69
69
69
69
69
69
69
60
60
69
69
56
56

Routine care
2.75
1.48
1.41
1.41
1.07
0.02
2.28
0.11
15.80
1.28
7.38
0.82
0.02
0.05
0.65
0.62
0.13
0.00
0.32
19.65
11.64
0.91

(14.39)
(15.51)
(12.72)
(2.82)
(2.49)
(0.10)
(3.30)
(1.09)
(127.23)
(19.52)
(37.85)
(4.45)
(0.18)
(0.41)
(2.68)
(4.13)
(0.87)
(0.01)
(2.65)
(77.16)
(262.87)
(7.34)

difference p  0.05.
BID, twice daily; QD, once daily; ALT/SGPT, alanine transaminase/serum glutamate pyruvate transaminase;
AST/SGOT, aspartate transaminase/serum glutamic oxaloacetic transaminase; GGT, -glutamyl transferase.
aTherapy-group
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ride, fasting glucose, urinalysis (UA) specific
gravity and uric acid analytes. For aspartate
transaminase, fasting glucose, and UA specific
gravity, there was a mean increase in duloxetinetreated patients and a mean decrease for routine
care-treated patients. For uric acid there was a
mean decrease in duloxetine-treated patients and
a mean increase in routine care-treated patients.
For chloride, there was a mean decrease for both
treatment groups and the mean decrease was
greater for duloxetine-treated patients.
Analysis of HbA1c and lipid profile. In the duloxetine therapy group, the only analyte with a slight
but significant mean difference compared to routine care was mean high-density lipoprotein
(HDL) cholesterol-dextran precip (HDL-DX) (p 
0.001). Both therapy groups experienced a decrease, with routine care patients experiencing a
greater decrease (mean change [SD]: 0.13 [0.19])
versus duloxetine-treated patients (mean change
[SD]: 0.02 [0.17]). No significant therapy-group
differences were observed in HbA1c, low-density
lipoprotein (LDL) cholesterol, and triglycerides.
Abnormal liver function tests. There were no
patients who experienced treatment-emergent
elevated bilirubin concomitant with treatmentemergent abnormal liver function tests. Three patients experienced an elevation in liver enzymes
greater than 3 times the Covance upper limit of
normal. Of these, two patients experienced an elevation in liver enzymes that were judged to be
unrelated to the study drug. The third patient had
elevated hepatic labs during the acute phase of
the trial, which began to decline during the drugtapering phase of the acute therapy period. When
the patient entered the open-label extension
phase and was rerandomized to routine care, the
patient continued in the trial with no further elevations in hepatic analytes.
Diabetic complication assessments.
Neuropathy screening instrument: During the
study, there were no significant therapy-group
differences observed in the mean change in the
MNSI score from baseline to endpoint.
Ophthalmologic examination: There were no significant therapy-group differences observed for
any of the ophthalmologic examination measures. These measures included worsening of visual acuity (left or right), required procedures
(macular laser surgery, panretinal photocoagula-
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tion, vitrectomy), reasons for photocoagulation
(neurovascularization, vitreous hemorrhage, or
other), and reasons for vitrectomy (vitreous hemorrhage, traction retinal detachment, or other).
Electrophysiology measure: There were no significant therapy-group differences observed for any
of the electrophysiology measures for either subset of patients. These measures included ulnar
F-wave, ulnar distal sensory latency, peroneal
F-wave, peroneal CMAP from baseline to end
point for a subset of randomly assigned patients
with data from the same limbs and for all randomly assigned patients.
Microalbumin/creatinine ratio: There was a statistically significant therapy-group difference observed in the change in microalbumin/creatinine
ratio from baseline to endpoint (p  0.027). For
the duloxetine therapy group, there was a mean
increase in microalbumin/creatinine ratio (mean
change [SD]: 0.05 [0.27]) that was not of a magnitude to be considered clinically relevant and patients continued to be well within normal limits
at end point. Routine care-treated patients experienced a slight mean decrease (mean change
[SD]: 0.01 [0.13]) from baseline to endpoint in
this ratio.
Vital signs, physical findings, and other observations related to safety.
Sitting blood pressure: Duloxetine-treated patients experienced a statistically significant (p 
0.049) but slight mean increase in diastolic blood
pressure (mean change [SD]: 1.39 [10.71]) compared to routine care-treated patients who experienced a slight mean decrease (mean change
[SD]: 1.76 [11.74]). Duloxetine-treated patients
also experienced a statistically significant (p 
0.010) but slight mean increase in pulse (mean
change [SD]: 1.70 [11.82]) compared to routine
care-treated patients who experienced a slight
mean decrease (mean change [SD]: 2.30 [11.29]).
These changes were not considered clinically relevant. There was no significant therapy-group
difference observed in mean change of systolic
blood pressure or weight.
Sustained elevation in blood pressure: One duloxetine-treated patient and no routine care-treated
patients met the definition of sustained elevation
in blood pressure and this difference was not statistically significant. The patient remained in the
study.
Electrocardiograms: Routine care-treated patients experienced statistically significant mean
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improvement compared to placebo on the 24hour average pain severity score. In addition, patients who completed one of the 12-week acute
therapy phase studies were rerandomized to duloxetine 60 mg BID or routine care for 52 weeks
of open-label treatment in order to evaluate the
safety of duloxetine over long-term administration.33 A phase 3, long-term, open-label, parallel
safety study of patients with DPNP was also performed, and the efficacy of duloxetine 60 mg BID
and 120 mg QD was observed for up to 28 weeks
in patients with DPNP via the Brief Pain Inventory (BPI) and the Clinical Global Impressions
(CGI) of Severity scale and both doses of duloxetine reduced BPI and CGI-Severity scores.34 All
these studies have provided evidence that duloxetine is efficacious, safe, and tolerable in the
management of DPNP.
In the study reported here, duloxetine was
well tolerated and safely administered in patients with DPNP during the 52-week open-label
extension therapy phase of this study. There
were no significant therapy-group differences
observed in any of the patient demographics or
disease characteristics, indicating that the therapy groups were comparable. No significant
therapy group differences were observed in the
physical or mental component scores or in any
of the SF-36 subscales or in the EQ-5D questionnaire. In a previous 52-week study of duloxetine
in the management of DPNP,33 duloxetine was
significantly better on the bodily pain subscale

increases in QT interval (mean change [SD]: 5.08
[24.98]; p  0.05), PR (mean change [SD]: 4.60
[17.62]; p  0.015), and QRS (mean change [SD]:
3.82 [10.07]; p  0.026) compared to duloxetinetreated patients. Duloxetine-treated patients experienced slight mean decreases in QT interval
(mean change [SD]: 1.50 [25.26]) and PR (mean
change [SD]: 0.81 [15.13]) and a slight mean increase in QRS (mean change [SD]: 0.97 [8.34]).
These changes were not clinically significant, and
there were no other ECG parameters that were
significantly different between therapy groups.
There were no significant therapy-group differences observed in potentially clinically significant
Fridericia corrected QT (QTcF) intervals.

Health outcomes
Table 6 summarizes the analysis of mean
change from baseline to endpoint on the SF-36
subscales and the EQ-5D. There were no statistically significant therapy-group differences observed in the SF-36 subscales or on the EQ-5D.

DISCUSSION
The effectiveness of duloxetine in the management of DPNP has been established in three 12week (acute therapy phase) double-blinded clinical studies.27–29 In these studies, duloxetine 60
mg QD and 60 mg BID demonstrated significant
TABLE 6.

MEAN CHANGE

IN

HEALTH OUTCOME MEASURES

Duloxetine
N  149
LS mean change
(SE)
Short Form 36 Health Status Survey
Mental Health
General Health Perceptionsb
Bodily Pain
Mental Component Summary
Physical Component Summary
Vitality
Social Functions
Physical Role Limit
Emotional Role Limit
Physical Functioning
Euro Quality of Lifec

4.18
3.58
0.05
3.26
1.32
2.54
5.30
1.65
5.99
4.03
0.02
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(1.29)
(1.37)
(1.78)
(0.76)
(0.73)
(1.62)
(1.81)
(3.22)
(3.20)
(1.90)
(0.02)

Routine care
N  68
LS mean change
(SE)
0.03
2.91
3.88
1.06
0.56
0.37
4.29
0.12
5.12
0.08
0.05

(1.88)
(2.00)
(2.60)
(1.11)
(1.06)
(2.37)
(2.64)
(4.70)
(4.68)
(2.77)
(0.03)

Group difference in LS
mean change from
baselinea
(95% CI)
4.22
0.66
3.83
2.21
1.87
2.17
1.02
1.53
0.87
4.11
0.02

(8.47, 0.04)
(5.2, 3.87)
(2.07, 9.72)
(4.71, 0.30)
(0.53, 4.28)
(7.54, 3.2)
(7, 4.97)
(9.14, 12.19)
(11.47, 9.72)
(2.17, 10.39)
(0.04, 0.09)

in least square (LS) means  Duloxetine LS Mean  Routine Care LS Mean.
interaction: p  0.094.
cTherapy-by-investigator interaction: p  0.010. Both interactions were attributed to outlying data for 3 patients
from a single site. Qualitative inferences were similar when this site was excluded from the analysis.
aDifferences

bTherapy-by-investigator
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of the SF-36 Health Status Survey, and duloxetine-treated patients perceived their general
health to be better than routine care-treated patients as measured by the EQ-5D version of the
Euro Quality of Life instrument.
Routine care-treated patients had a longer
mean duration of exposure compared to duloxetine-treated patients. This may have been because
routine care-treated patients were allowed to
switch therapies without discontinuing from the
study, whereas patients in the duloxetine therapy
group could not be prescribed certain other treatments. There were no significant therapy-group
differences observed in the overall incidence of
TEAEs. Most TEAEs were mild or moderate in
severity, and the TEAE reported by 10% or more
of duloxetine-treated patients was nausea
whereas in routine care-treated patients was peripheral edema, pain in extremity, somnolence,
and dizziness. These findings are consistent with
the known side effect profiles of duloxetine and
gabapentin, the most commonly used drug in the
routine care-treated group. Nausea was also the
most frequently reported TEAE in the acute therapy phase studies, although nausea tended to
appear early in treatment and subside quickly.
Hypertension was reported as a TEAE in 3.1%
duloxetine- and 2.6% routine care-treated patients. A significantly higher percentage of routine care-treated patients experienced 1 or more
SAE with the single event congestive heart failure. Two routine care-treated patients reported
hypertension as a SAE. There were no significant
therapy-group differences observed in the overall incidence of discontinuation due to adverse
events or for any single event.
The reported death rate of 1960.0 (per 100,000
patient–years) is about twice as high as the age
adjusted death rate of 853.3 for all causes between
2000 and 2002.35 The risk for death among people
with diabetes is about two times that of people
without diabetes.36 Thus, the observed death rate
in this study is what would be expected of a population of patients with diabetes, and may actually be lower than expected if one considers that
disease in these patients is more likely to be more
advanced than in the overall diabetic population.
The observation that the death rate in the routine
care-treated group was about twice as high as in
the duloxetine-treated group is probably an artifact related to the low number of events.
Although duloxetine-treated patients experienced significant mean changes in a few chem-
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istry analytes, these were not associated with
clinical findings and these changes were of insufficient magnitude to have clinical relevance or
represent systemic drug toxicity. Transaminase
increases were not associated with increases in
bilirubin. Duloxetine did not appear to adversely
affect glycemic control or lipid profiles. The use
of duloxetine appears to be associated with a
small increase in fasting glucose in this study,
similar to that seen in an earlier study.34 None of
these changes in analyte concentrations were of
sufficient magnitude to have clinical relevance.
Overall diabetes control does not appear to be affected, as evidenced by the lack of any meaningful changes in HbA1c.
Duloxetine-treated patients experienced a
slight, but significant mean increase in diastolic
blood pressure and pulse compared with routine
care-treated patients. Neither of these effects was
considered clinically relevant. No significant
therapy-group differences were observed in sustained elevation in blood pressure. The observed
increase in pulse rate for the duloxetine-treated
patients could be expected due to elevations in
NE tone.37 These results are supportive of earlier
clinical trials with duloxetine22–25,27–29 and suggest that duloxetine has a safe cardiovascular profile. Routine care-treated patients experienced
significantly higher mean changes in QT, PR, and
QRS intervals compared with duloxetine-treated
patients. No other ECG parameters were significantly different between therapy groups, and no
significant therapy-group differences were observed in potentially clinically significant QTcF
intervals. The lack of significant cardiovascular
changes due to duloxetine therapy in these patients suggests that patients with diabetes mellitus do not require more intensive assessment of
their cardiovascular status when treated with duloxetine, than they require for their underlying
diabetes. There were no significant therapygroup differences observed in the MNSI, ophthalmologic, and electrophysiologic measures.
The diabetic complications assessments demonstrated that duloxetine does not appear to adversely affect nerve function or the course of
DPNP, nor does it change the progression of retinopathy.
Although caution must be used when interpreting results in an open-label study, the results
of this trial corroborate previous studies that duloxetine is safe and well tolerated in the management of patients with DPNP. In the previously
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reported 52-week study comparing duloxetine 60
mg BID to routine care in the management of
DPNP, duloxetine performed as well as routine
care on most measures of safety, and the duloxetine-treated group had significantly higher
scores on the SF-36 bodily pain subscale and on
the EQ-5D.33 In the earlier study, there were no
adverse events that were reported significantly
more frequently in duloxetine-treated patients
compared with routine care-treated patients. The
study reported here provides additional evidence
that duloxetine is safe for long-term therapy of
patients at least 18 years old diagnosed with
DPNP, and the overall safety profile reported
here appears to be similar to that observed in major depressive disorder patients22–25,38 as well as
in that observed in other double-blind placebocontrolled studies of duloxetine in patients with
DPNP.27,28

ACKNOWLEDGMENTS
The authors thank the Duloxetine Product
Team for their contributions to the design and implementation of this clinical trial, the clinical investigators, the staff, and the many patients for
their participation in this clinical trial.
The Trial Investigators included: Ricardo Ayala, M.D., AMO Corporation, Louise Beckett,
M.D., IPS Research Co., E. Richard Blonsky, M.D.
The Pain & Rehabilitation Clinic of Chicago, M.
Arthur Charles, M.D., Ph.D., University Clinical
Investigators, Martin J. Conway, M.D., Lovelace
Scientific Resources, Michael J. Disciglio, M.D.,
Shore Health Group, David L. Fried, M.D.,
Omega Medical Research, Larry I. Gilderman,
D.O., University Clinical Research Assoc. Inc., Julia M. Hutchinson, M.D., Independent Practice,
Ronica M. Kluge, M.D., Clinical Physiology Associates Clinical Study Center, Kwame Osei,
M.D., FACE, FACP, The Ohio State University
College of Medicine, John T. Cecil, Jr., M.D., Four
Rivers Clinical Research, Bruce G. Rankin, D.O.,
University Clinical Research Assoc. Inc., Jon Russell, M.D., Ph.D., The University of Texas Health
Science Center—San Antonio, Richard A. Sachson, M.D., Research Institute of Dallas, Richard
M. Bergenstal, M.D., International Diabetes Center, Stephan C. Sharp, M.D., Clinical Research Associates, Rubens Sievert, M.D., Winthrop University Hospital, Timothy R. Smith, M.D., Mercy
Health Research, Norman G. Soler, M.D., Ph.D.,

39

Springfield Diabetes & Endocrine Center,
Lawrence Sherman, M.D., Radiant Research,
Richard L. Weinstein, M.D., Diablo Clinical Research Inc., John Eric Liljenquist, M.D., Rocky
Mountain Institute of Clinical Research, Andrew
H. Zwick, M.D., Clinical Trails Management of
Boca Raton, Inc., Lissette Jimenez. M.D., RCMI—
Clinical Research Center University District Hospital, Elizabeth A. Barranco Santana, M.D., Ponce
School of Medicine.

REFERENCES
1. National Diabetes Information Clearinghouse
(NDIC): National Diabetes Statistics: Total prevalence
of diabetes in the United States, All Ages, 2002.
www.diabetes.niddk.nih.gov/dm/pubs/statistics/
index.htm#7 (Last accessed November 8, 2005).
2. Clark CM, Lee DA: Prevention and treatment of the
complications of diabetes mellitus. N Engl J Med
1995;332:1210–1217.
3. Boulton AJM, Rayaz AM, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 2004;27:
1458–1486.
4. Eastman RC: Diabetes in America, 2nd ed. NIH Publication No. 95-1468, 1995, pp. 339–348.
5. Callisi PT, Jaber LA: Peripheral diabetic neuropathy:
current concepts in treatment. Ann Pharmacother
1995;29:769–777.
6. Courteix C, Eschalier A, Laverenne J: Streptozocin-induced diabetic rats: Behavioral evidence for a model
of chronic pain. Pain 1993;53:81–88.
7. Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal
nerve ligation in the rat. Pain 1992;50:355–363.
8. Basbaum AI, Fields HL: Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309–338.
9. Clark FM, Proudfit HK: The projections of noradrenergic neurons in the A5 catecholamine cell group to
the spinal cord in the rat: Anatomical evidence that
A5 neurons modulate nociception. Brain Res 1993;
616:200–210.
10. Coderre TJ, Katz J: Peripheral and central hyperexcitability: Differential signs and symptoms in persistent pain. Behav Brain Sci 1997;20:404–419.
11. Max MB, Kishore-Kumar R, Schafer SC, Meister B,
Gracely RH, Smoller B, Dubner R: Efficacy of desipramine in painful diabetic neuropathy: A placebocontrolled trial. Pain 1991;45:3–9.
12. Lynch ME: Antidepressants as analgesics: A review
of randomized controlled trials. J Psychiatry Neurosci
2001;26:30–36.
13. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med
1992;326:1250–1256.

40
14. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS:
Venlafaxine versus imipramine in painful polyneuropathy. Neurology 2003;60:1284–1289.
15. Backonja M-M: Use of anticonvulsants for treatment
of neuropathic pain. Neurology 2002;59(Suppl 2):S14–
S17.
16. Tremont-Lukats I, Megeff C, Backonja M-M: Anticonvulsants for neuropathic pain. syndromes: Mechanisms of action and place in therapy. Drugs 2000;
60:1029–1052.
17. Stone KJ, Viera AJ, Parman CL: Off-label applications
for SSRIs. Am Fam Physician 2003;68:498–504.
18. Watson CPN, Moulin D, Watt-Watson J, Gordon A,
Eisenhoffer J: Controlled-release oxycodone relieves
neuropathic pain: A randomized controlled trial in
painful diabetic neuropathy. Pain 2003;105:71–78.
19. Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy.
Neurology 2003;60:927–934.
20. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid
CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290:1757–1762.
21. Wong DT, Bymaster FP: Dual serotonin and noradrenaline uptake inhibitor class of antidepressants—
Potential for greater efficacy or just hype? Prog Drug
Res 2002;58:169–222.
22. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack
MA: Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebocontrolled trial. J Clin Psychiatry 2002;63:308–315.
23. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383–390.
24. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA:
Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry
2002;63:225–231.
25. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt
C, Demitrack MA: Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:
389–399.
26. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson
MB: Duloxetine in the long-term treatment of major
depressive disorder. J Clin Psychiatry 2003;64:1237–
1244.
27. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S: Duloxetine vs. placebo in patients with painful diabetic
neuropathy. Pain 2005;116:109–118.
28. Wernicke J, Lu Y, D’Souza D, Waninger A, Tran P:
Antidepressants: Duloxetine at doses of 60 mg QD
and 60 mg BID is effective in the treatment of diabetic
neuropathic pain (DNP). J Pain 2004;5(Suppl 1):S48.

RASKIN ET AL.
29. Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger
AL, Iyengar S, Wernicke JF: A double-blind, randomized multicenter trial comparing duloxetine with
placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346–356.
30. Feldman EL, Stevens MJ, Thomas PK, Brown MB,
Canal N, Greene DA: A practical two-step quantitative clinical and electrophysiological assessment for
the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281–1289.
31. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36
Health Survey Manual and Interpretation Guide. Boston,
MA: The Health Institute, New England Medical Center, 1993.
32. Kind P: The EuroQoL instrument: an index of healthrelated quality of life. In: Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996, pp. 191–201.
33. Wernicke J, Rosen A, Lu Y, Lee T, Iyengar S, Knopp
K, Goldstein D: The safety of duloxetine in the longterm treatment of diabetic neuropathic pain. J Pain
2004; 5(Issue 3, Suppl 1), S48; Presentation at the
American Academy of Pain Medicine. Orlando, FL:
March 3–7, 2004.
34. Raskin J, Wang F, Pritchett YL, Goldstein DJ: Duloxetine for patients with diabetic peripheral neuropathic
pain: A 6-month open-label safety study. Pain Med
(in press).
35. National Center for Health Statistics: Health, United
States, 2004 With Chartbook on Trends in the Health
of Americans. Hyattsville. MD: 2004.
36. National Diabetes Information Clearinghouse
(NDIC): National Diabetes Statistics: Deaths Among
People with Diabetes, United States, 2000. www.
diabetes.niddk.nih.gov/dm/pubs/statistics/index.h
tm#7 (Last accessed November 8, 2005).
37. Chalon SA, Granier LA, Vandenhende FR, Bieck PR,
Bymaster FP, Joliat MJ, Hirth C, Potter WZ: Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled
study. Neuropsychopharmacology 2003;28:1685–1693.
38. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ,
Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the
treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106–132.

Address reprint requests to:
Joel Raskin, M.D.
Eli Lilly and Company
3650 Danforth Avenue
Toronto, Ontario
Canada M1N 2E8
E-mail: raskin_joel@lilly.com

